Introduction Sofosbuvir is a new direct-acting pyrimidine nucleotide analogue antiviral drug that has shown remarkable efficacy in the treatment of hepatitis C in clinical trials. However, observational anecdotal data have recently suggested an increased risk of serious bradycardia among patients treated with sofosbuvir and amiodarone. Objective We aimed to estimate and characterize the cardiac safety of sofosbuvir by performing a systematic review of randomized controlled trials (RCTs).
Introduction
Sofosbuvir is a direct-acting pyrimidine nucleotide analogue antiviral drug approved to treat patients with chronic hepatitis C virus (HCV) infection. When administered in combination with a second direct-acting antiviral (DAA) agent, with and without pegylated interferon (pegIFN), sofosbuvir showed remarkable efficacy, with more than 90% of previously untreated patients with HCV infection achieving sustained virologic response [1] .
In March 2015, the US FDA issued a label update for sofosbuvir following a series of reports from Gilead Science, Inc. describing symptomatic bradycardia events in nine patients treated with sofosbuvir with another DAA and amiodarone [2] . In this update, bradycardia events were said to occur generally within hours to days, and a safety recommendation was made for patients who receive amiodarone to undergo cardiac monitoring for 48 h after first administration [2] .
These warnings were based on anecdotal case reports or small case series [3, 4] . However, uncertainty exists regarding the pathophysiological mechanisms underlying this putative association between sofosbuvir and cardiac/ bradycardia events.
Therefore, we aimed to better estimate the risk of cardiac harms, with a special focus on arrhythmias, associated with sofosbuvir treatment by performing a systematic review of all randomized controlled trials (RCTs) comparing sofosbuvir with a control arm, independent of baseline conditions.
Methods
This systematic review with meta-analysis was performed using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework guidelines for reporting guidance [5] and its extension for improving harms reporting in systematic reviews (PRISMA harms) [6] .
This systematic review was registered on PROSPERO (PROSPERO 2016: CRD42016033109), and the protocol can be accessed at http://www.crd.york.ac.uk/PROSPERO/ display_record.asp?ID=CRD42016033109.
Eligibility Criteria
We considered for inclusion all parallel-design RCTs comparing any sofosbuvir-containing regimen (including sofosbuvir alone or with other active drugs, irrespective of the dose, treatment duration, or route of administration) with a non-sofosbuvir control arm (either placebo or no treatment). Studies were excluded if both arms were exposed to sofosbuvir or if none of the cardiac safety outcomes of interest was reported.
Cardiac safety was assessed by quantifying the risk of overall cardiac events [according to Medical Dictionary for Regulatory Activities (MedDRA Ò ) system organ class (SOC)] reported in the RCTs, as well as the risk for arrhythmic events [3, 7] , bradycardia [3, 7] , and tachycardia and extrasystoles (ventricular or supraventricular). Symptoms such as syncope, presyncope, and loss of consciousness were also evaluated as potential surrogates of arrhythmic events.
Search Method
Potential eligible studies were found via an electronic search of the MEDLINE, Embase, and Cochrane Library (CENTRAL) databases in January 2017. The search strategy [see the Electronic Supplementary Material (ESM) 1] included free-text and medical subject heading (MeSH) terms without language restrictions. RCTs were identified through methods that have been published previously [8, 9] . We also checked ClinicalTrials.gov, public assessment reports, and the reference lists of included studies and other literature reviews for other potential studies and contacted the manufacturer's clinical research department to obtain further unpublished data.
Data Extraction, Evaluation, and Synthesis
Titles and abstract were screened independently by groups of authors (DC, FBR, and MB; MMD, and CS). The full texts of RCTs that potentially fulfilled the inclusion criteria were further assessed. When multiple reports concerned one eligible study, we chose the report with (1) the studied data, (2) the largest sample size, and (3) the longest followup. Data from multiple studies within a single report were only used if the data of interest were not available from individual trials. Study characteristics and outcomes were extracted independently by groups of authors (DC, FBR, and MB; MMD, and CS). Study quality was checked by DC and FBR. As anticipated, different terms were used for the same adverse event. Therefore, in addition to an individual appraisal of such data, we aggregated the reported adverse events into clinically meaningful groups/outcomes/ symptoms, such as arrhythmias, bradycardia, and tachycardia or extrasystoles. For example, if palpitations were reported as an adverse event, and further information was provided for its cause, e.g., sinus tachycardia, we classified this adverse event into two different categories.
Risk of Bias in Individual Studies
We used the Cochrane tool to assess the risk of bias of included studies [10] . The six predefined specific domains of analysis were random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting, and we added a domain to assess whether the events were independently adjudicated. Critical appraisal was performed independently by two authors (DC and FBR). Any disagreement was solved by discussion and, if necessary, consensus was reached with the participation of a third reviewer (JC). The risk of bias was qualitatively evaluated as high, unclear, or low. Risk-ofbias graphs were derived from this tool.
Statistical Analysis
We used RevMan 5.3.3 software to calculate estimates and pooled analyses estimates for individual studies. Results were reported using risk ratios (RRs) and 95% confidence intervals (CIs). RR was chosen as an effect measure for the primary analysis because of the greater similarity of relative estimates between studies with different designs, populations, and lengths of follow-up [11] . Raw data from studies were converted to RRs, and random-effects pooled meta-analysis was performed, irrespective of the statistical heterogeneity, as assessed with the I 2 test [12] . When one of the therapeutic arms presented zero events, a fixed value of 0.5 was added to avoid computational problems in the relative risk estimations [13] [14] [15] . As the events of interest are deemed to be infrequent, and to indirectly assess the robustness of the results found in primary analysis with the above-mentioned methods [16] , we also derived pooled estimates using the following alternative methods: (1) Mantel-Haenszel fixed-effects meta-analysis using the odds ratio (OR); (2) Peto's OR [13] ; (3) Poisson randomeffects models for meta-analysis using the software R version 3.1.3, assuming similarities in the RR and incident RR in the case of rare events [17] ; and (4) random-effects meta-analysis using the risk difference (RD) measure, to overcome the problems of zero events in both arms [18] .
We undertook univariate meta-regression of the treatment effect with demographic characteristics (age or proportion of males), clinical characteristics (proportion of patients with cirrhosis), or concomitant treatment (sofosbuvir with ribavirin) to explore the impact of these variables.
Assessment of Confidence in Cumulative Evidence
As recommended by the GRADE (Grading of Recommendations Assessment, Development and Evaluation) working group methodology [19, 20] , two reviewers (DC and FBR) independently assessed all of the critical outcomes in the following domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias.
Where the authors disagreed, they reached consensus by consulting an independent third reviewer if necessary (JC). For this purpose, we used the GRADEprofiler (GRADEpro) software tool, and data were then extracted into the form of a summary of findings table for inclusion in the review manuscript. We applied the standard definitions for quality of evidence [21] and explicit criteria to ensure the consistency and reproducibility of GRADE judgements for each domain and for all key comparisons of the critical outcomes (ESM 2).
Results

Included Trials
Overall, six trials with 2346 patients fulfilled the inclusion criteria ( Fig. 1 ) [22] [23] [24] [25] [26] [27] . A total of 1625 patients were treated with sofosbuvir, either alone or in combination with other agents, such as ribavirin ± pegIFN (57%), velpatasvir (38%), or ledipasvir (5%). Among controls, 349 patients were treated with placebo (four trials), 243 were treated with a combination of interferon and ribavirin (one trial), and 129 patients received a combination of elbasvir and grazoprevir (one trial).
The mean age of patients in the trials ranged from 48 to 64 years, and the proportion of patients with cirrhosis ranged from 16 to 100% among the trials. Table 1 overviews the characteristics of the included trials.
Risk of Bias
The overall risk of bias across studies was moderate. The included trials used different methodologic approaches, which limits, at least partially, the robustness of data. All trials used adequate methods to randomize to therapeutic arms, but three trials were unblinded for the randomized arms: both FISSION and C-EDGE Head-2-Head trials had a priori an open-label design [23, 27] , and, in the VALENCE study [24] , randomization codes were revealed to terminate with the placebo arm because of the efficacy data reported in the FISSION trial [23] . In these trials, any adverse events could be reported unblinded. None of the outcomes of interest of this systematic review was previously determined, and thus such events were not actively searched. None of the adverse events reported was independently adjudicated. Figure 2 details the risk-of-bias assessment, and Fig. 1 in the ESM overviews the proportion of included trials that were at low or high risk of bias for each domain ascertained.
Primary Analysis
The pooled analysis included both published and unpublished data (provided by Gilead Sciences, Inc.) from the six RCTs and showed that sofosbuvir was not associated with an increased risk of reported cardiac events (SOC cardiac), with an RR of 0.87 (95% CI 0.41-1.85; I 2 = 7%; six RCTs; n = 2346) (Fig. 3) . The risk of overall arrhythmic events also did not differ between sofosbuvir regimens and non-sofosbuvir treatments (RR 0.93; 95% CI 0.34-2.51; I 2 = 0%; five RCTs; n = 2091). As for bradycardia, only the FISSION trial reported such events: one sinus bradycardia in each arm and one complete atrioventricular block in the interferon and ribavirin arm (non-sofosbuvir arm) [23] . The RR for bradycardia was 0.47 (95% CI 0.04-5.20; one RCT; n = 499).
The pooled relative risk of tachycardia (RR 0.91; 95% CI 0.20-4.20; I 2 = 0%; three RCTs; n = 1196) and extrasystoles (RR 1.22; 95% CI 0.25-5.89; I 2 = 0%; four RCTs; n = 2091) did not significantly differ among sofosbuvir and non-sofosbuvir regimens.
Symptoms reported as adverse events potentially related to arrhythmias such as syncope, presyncope, or loss of consciousness were reported in three trials (Fig. 4) . The pooled analyses of both individual outcomes (Fig. 2 in the ESM) and the composite of such reported adverse events (RR 0.70; 95% CI 0.26-1.88; I 2 = 0%; three RCTs; n = 1517) did not show an increased risk with sofosbuvir treatment. Similarly, the relative frequency of palpitations as a reported adverse event was not increased with sofosbuvir (RR 0.62; 95% CI 0.24-1.60; I 2 = 0%; four RCTs; n = 1936). 
Additional Analyses
The results from pooled analyses using alternative methods and/or estimate measures were similar to the findings of the primary analysis, without significant differences between groups for all outcomes ( Table 2) .
Meta-regression treatment effects with age, sex, cirrhosis stage, and the concomitant use of ribavirin and sofosbuvir did not influence significantly these variables in the meta-analyses results ( Table 1 in the ESM).
Assessment of Confidence in Cumulative Evidence
Supplementary Table 2 details the GRADE approach for the quality of the available evidence, which was considered to be very low.
Discussion
This systematic review overviewed cardiac events thataccording to the latest reports [3, 7] -are of concern in patients treated with sofosbuvir. The pooled data did not show a significant increased risk of cardiac harms with sofosbuvir. Among the cardiac adverse events, arrhythmias, predominantly severe bradyarrhythmia, were deemed to be associated with sofosbuvir circumstances. Our systematic review and meta-analysis of RCTs evaluating sofosbuvir and non-sofosbuvir regimens (including placebo) did not raise any safety concerns regarding cardiac, arrhythmic, or bradycardia risk.
Complementarily, the analysis of reported adverse events related to symptoms linked to (but not pathognomonic of) dysrhythmias, such as syncope, presyncope, loss of consciousness, and palpitations, was ELB elbasvir, GRA grazoprevir, HCV hepatitis C virus, LED ledispavir, PEGIFN pegylated interferon, PL placebo, pt(s) patient(s), RCT randomized controlled trial, RIB ribavirin, SOF sofosbuvir, SVR sustained viral response, tx treatment, VEL velpatasvir, wk week unremarkable for any safety warning issue, despite the acknowledged limitations (see Sect. 4.1). However, the risk of arrhythmic events in patients with chronic liver disease and the potential causality with sofosbuvir (with or without amiodarone) should be addressed, recognizing that some bias and drawbacks may exist. First, arrhythmias are not unusual in patients with chronic liver disease, including cirrhosis [28] [29] [30] [31] , and it is also known that the use of non-selective beta-blockers to decrease the portal pressure further impairs cardiac chronotropism and dromotropism [32] . Second, events also occur in patients who are not receiving amiodarone [7] . Third, the causality relationship between sofosbuvir (and amiodarone) and the onset of bradycardia in the case reports and case series was not definite [3, 7, 33] . Other factors also impair the robustness of conclusions: publication bias and inability to exclude other potential sources of bias (e.g., paroxysmal nature of bradyarrhythmias in some patients). Thus, a reasonable uncertainty exists regarding sofosbuvir and the risk of cardiac/arrhythmic/ bradycardic events.
Still, in 2015, the FDA issued a label update for both sofosbuvir and the combination of sofosbuvir and ledipasvir [34] . Gilead Sciences, Inc. also issued a warning letter to physicians advising that both formulations of sofosbuvir may cause potentially fatal heart arrhythmias. Meanwhile, basic science and animal studies reported that the potential mechanisms may be related to drug-drug interactions through p-glycoprotein in cardiac myocytes [33] or direct action in the sino-atrial/atrioventricular node [35, 36] .
In our opinion, the present findings are of utmost clinical relevance: DAAs are becoming the standard of care for hepatitis C treatment, and the number of patients exposed to sofosbuvir is expected to increase in a proportion that exceeds the number of patients included in the clinical trials. It is worth noting that the possibility of a small absolute risk increase is not excluded by our analysis, and therefore phase IV trials with longer follow-up or larger observational studies or registries (such as the Gilead Sustained Virologic Response Registry-ClinicalTrials.-gov identifier NCT01457755) may contribute more robust data to the evaluation of cardiac risks associated with DAAs, particularly sofosbuvir, as they may able to capture more of these rare adverse events.
Limitations
The results and conclusions presented here are weakened by the limitations inherent to meta-analyses and individual studies.
The patients included in the RCT are already a selected cluster and may not be representative of all candidates for sofosbuvir. The coexistence of hepatitis C and cardiac disease and/or the requirement of cardiac drugs it is not expected to be uncommon. These patients (including amiodarone users) were excluded from the trials evaluated in this review ( Table 3 in the ESM).
A higher risk of bias was found for potential selective reporting of outcomes. A key limitation is that no single RCT was primarily designed to assess the cardiac/arrhythmic safety of sofosbuvir, and these outcomes were not Fig. 2 Risk-of-bias assessment results of each trial. Green symbols are associated with a low risk of bias, and red symbols mean a high risk of bias c Fig. 3 Forest plot evaluating the relative risk of reported cardiac events, arrhythmias, bradycardia, tachycardia, and extrasystoles. The plots show the total number of patients included in the trials, but the number of patients included for each analysis are detailed in the text. CI confidence interval, M-H Mantel-Haenszel, SOC system organ class actively searched and were reported at the discretion of the investigator. Therefore, it is unclear whether failure to report a particular adverse event means there were no such events or simply that such events were not included as a measured endpoint. The exclusion of studies without any reported outcomes may contribute to an increased risk of selective reporting bias, but the inclusion of such using other methods and measures (as provided in RD) yields poor statistical power, which makes them unsuitable for meta-analysis of rare events [14, 37] .
Another limitation of our findings is related to the low rates of cardiac events. In the sofosbuvir arms, the risk of overall cardiac events was about 2.0%. In fact, one of the features that precluded robust conclusion was the low number of patients enrolled in all the included trials. This was one of the determinants considered for grading the confidence of the cumulative data as very low for all outcomes using the GRADE tool ( Table 2 in the ESM) [21] . Although the data from cardiac safety warnings point towards potential short-term cardiac adverse events, it should be acknowledged that the follow-up period was considerably short and does not rule out the risk of longterm cardiac events. Regardless, and considering all these limitations, our results represent the best possible available Data in parentheses are 95% confidence intervals CI confidence interval, MH Mantel-Haenszel, NA not available due to limitations inherent to the Poisson model random-effects pooled analysis, OR odds ratio, RR risk ratio, SOC system organ class evidence about this topic, which was raised by anecdotic case reports of potential idiosyncratic reactions that occurred in the first 48 h in patients receiving amiodarone and sofosbuvir.
Conclusions
Pooled data from RCTs did not show an increased risk of short-term cardiac events (including [brady]arrhythmias) with sofosbuvir. The robustness of this conclusion is precluded by the low confidence in the cumulative data based on GRADE evaluation, and phase IV trials with longer follow-up times or large observational studies/registries are required.
